The policy of placing older donors into older recipients: is it worth the risk?

Clin Transplant. 2014 Jul;28(7):802-7. doi: 10.1111/ctr.12382. Epub 2014 Jun 1.

Abstract

Background: To expand the donor pool, older donors (≥50 yr) are frequently used in older recipients (≥60 yr). Older recipients and those receiving older donor hearts have independently displayed decreased post-transplant survival. However, outcomes in older patients receiving older donor hearts are contentious.

Methods: Eight hundred and seventy-nine heart transplant patients between 2000 and 2010 were analyzed, excluding patients with donor coronary artery disease. From 380 patients ≥60 yr, 327 patients with donors <50 yr old were compared with 53 patients with donors ≥50 yr old for: five-yr actuarial survival, freedom from cardiac allograft vasculopathy (CAV: stenosis ≥30%), non-fatal major adverse cardiac events (NF-MACE: MI, CHF, stroke, need for pacemaker/ICD), one-yr freedom from any treated rejection.

Results: The older vs. younger donor group demonstrated significantly lower five-yr survival (57% vs. 85%, p < 0.001) and freedom from CAV (83% vs. 92%, p = 0.03). No difference was observed in five-yr freedom from NF-MACE and one-yr freedom from any treated rejection. Multivariate analysis found donor age ≥50 to be an independent risk factor for death (HR 1.8, CI 1.1-2.9, p = 0.008) and CAV (HR 1.9, CI 1.2-2.9, p = 0.004).

Conclusions: Use of older donors (≥50 yr) in older recipients (≥60 yr) results in lower five-yr survival and freedom from CAV. Caution is required in these cases. Larger studies are warranted to confirm findings.

Keywords: cardiac allograft vasculopathy; cardiac transplantation; older donors; older recipients; outcomes; rejection; survival.

Publication types

  • Comparative Study

MeSH terms

  • Age Factors
  • Aged
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Graft Rejection*
  • Graft Survival*
  • Heart Diseases / surgery*
  • Heart Transplantation*
  • Humans
  • Male
  • Middle Aged
  • Postoperative Complications*
  • Prognosis
  • Risk Factors
  • Survival Rate
  • Time Factors
  • Tissue Donors*